R1 RCM Inc. Nasdaq

Equities

RCM

US7493971052

Healthcare Facilities & Services

Real-time Estimate Cboe BZX Other stock markets 03:42:32 2024-04-25 pm EDT			5-day change	1st Jan Change
11.8 ^USD	-0.38%		-2.63%	-50.04%

Apr. 18	R1 RCM's Q1 Results to Focus on Strategic Alternatives, Change Cyberattack, RBC Says	MT
Apr. 11	North American Morning Briefing : Stock Futures -2-	DJ

R1 RCM Inc. Provides Earnings Outlook for the Year 2021

February 18, 2021 at 07:00 am EST

R1 RCM Inc. provided earnings outlook for the year 2021. For the period, the company expects to generate Revenue of between $1,410 million and $1,460 million. GAAP operating income of $135 million to $155 million.

Latest news about R1 RCM Inc.

R1 RCM's Q1 Results to Focus on Strategic Alternatives, Change Cyberattack, RBC Says	Apr. 18	MT
North American Morning Briefing : Stock Futures -2-	Apr. 11	DJ
KeyBanc Downgrades R1 RCM to Sector Weight From Overweight on Potential Risks to Hospital End Markets	Apr. 10	MT
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
North American Morning Briefing : Investors -2-	Mar. 21	DJ
News Highlights : Top Financial Services News of the Day - Thursday at 12 AM ET	Mar. 21	DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 4 PM ET	Mar. 20	DJ
Canaccord Genuity Trims Price Target on R1 RCM to $16 From $17, Maintains Buy Rating	Mar. 20	MT
Citigroup Upgrades R1 RCM to Buy From Neutral, Price Target is $16	Mar. 20	MT
R1 RCM Calls for Halt to Talks About Potential Deal	Mar. 19	MT
Transcript : R1 RCM Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 04:35 PM	Mar. 13
R1 RCM Forms Special Committee to Evaluate Strategic Alternatives	Mar. 11	MT
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Truist Securities Downgrades R1 RCM to Hold From Buy, Price Target is $16	Mar. 05	MT
Transcript : R1 RCM Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM	Mar. 04
KeyBanc Raises Price Target on R1 RCM to $17 From $13, Maintains Overweight Rating	Feb. 29	MT
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Barclays Downgrades R1 RCM to Equalweight From Overweight, Price Target is $14	Feb. 28	MT
Evercore ISI Downgrades R1 RCM to In Line From Outperform, Raises Price Target to $16 From $12	Feb. 28	MT
Deutsche Bank Downgrades R1 RCM to Hold From Buy, $15 Price Target	Feb. 27	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Feb. 27	MT
R1 RCM Reports Breakeven Q4 Earnings; Revenue Rises; 2024 Outlook Issued, Shares Advance Pre-Bell	Feb. 27	MT
Transcript : R1 RCM Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024	Feb. 27	CI
R1 RCM Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI

Chart R1 RCM Inc.

Duration

Period

More charts

Company Profile

R1 RCM Inc. is a provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups. The Companyâs scalable operating models seamlessly complement a healthcare organizationâs infrastructure, driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. The Company delivers solutions to customers through technology, intellectual property (IP), global scale, and operational excellence. Its Intelligent Automation modernizes processes, removes friction, and simplifies revenue cycle management (RCM). Its use of artificial intelligence (AI) in its platform depends on the availability and pricing of equipment and technical infrastructure from third parties, including Microsoft Azure. It serves over 3,700 hospitals, including 93 of the top 100 health systems, and over 30,000 physicians.

Sector

Healthcare Facilities & Services

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for R1 RCM Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.84 USD

Average target price

16.93 USD

Spread / Average Target

+42.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
CVS HEALTH CORPORATION	-14.87%	85.42B
HCA HEALTHCARE, INC.	+16.32%	84.38B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.39B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.46%	17.49B
FRESENIUS SE & CO. KGAA	-3.17%	16.44B
QUEST DIAGNOSTICS INCORPORATED	-1.73%	15.28B
FRESENIUS MEDICAL CARE AG	-0.45%	12.22B
PURE HEALTH HOLDING	-31.23%	11.98B
EUROFINS SCIENTIFIC SE	-2.51%	11.71B

Other Healthcare Facilities & Services